Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of the International AIDS Society
Published in: Journal of the International AIDS Society 4/2010

Open Access 01-12-2010 | Poster presentation

Incidence of ischemic cardiovascular events in the maraviroc clinical development program

Authors: S Portsmouth, R Burnside, A Lazzarin, M Johnson, H Valdez

Published in: Journal of the International AIDS Society | Special Issue 4/2010

Login to get access

Excerpt

Maraviroc (MVC), a CCR5 antagonist, does not appear to adversely affect serum lipids and may decrease LDL cholesterol in dyslipidemic subjects. The CCR5-del32 polymorphism, resulting in reduced (heterozygous) or absent (homozygous) CCR5 expression, is associated with reduced risk of cardiovascular disease. An early imbalance of cardiovascular adverse events was noted in the MVC phase 2b development program at 24 weeks. We investigated the longer term risk of cardiovascular events in MVC recipients in the development program. The D:A:D study and other cohorts have reported an incidence of 3.6/1000 PY for myocardial infarction (MI) among patients on HAART. …
Metadata
Title
Incidence of ischemic cardiovascular events in the maraviroc clinical development program
Authors
S Portsmouth
R Burnside
A Lazzarin
M Johnson
H Valdez
Publication date
01-12-2010
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1758-2652-13-S4-P65

Other articles of this Special Issue 4/2010

Journal of the International AIDS Society 4/2010 Go to the issue

Oral presentation

Highlights of the 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, London, November 2010

Oral presentation

Vitamin D and HIV: shine a light

Poster presentation

Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study

Poster presentation

Feasibility of testing antibodies to HIV from filter paper using HIV rapid test kits

Poster presentation

Nitric oxide protects against HIV gp120 endothelial injury

Poster presentation

Cross-sectional study of HIV living people cohort to specify indications to antiretroviral treatment in naïve patients
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits